Clinical trials
Patient clinical trials
Below are recruiting patient clinical trials, each written for real people, not researchers. We’re tracking 14,857 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05767203Recruiting
Study genetic and blood markers in people with inherited intellectual disability
This study looks at genetic-related and blood/biologic markers in people with an inherited (genetic) intellectual disability. The goal is to better understand these differences and how they might relate to the condition.
ParisAges Any age - NCT05766748RecruitingPhase 1/Phase 2
Azeliragon trial for pancreatic cancer after prior treatments failed
This trial tests azeliragon in people whose pancreatic cancer has spread or grown locally and who did not respond well to earlier chemotherapy. It aims to see whether the drug can help control the cancer and be tolerated after prior treatment.
Los Angeles, CaliforniaAges 18–80 - NCT05768087Recruiting
Testing higher-dose proton radiation for new glioblastoma
This trial is testing an escalated dose of proton beam radiation, along with standard chemotherapy and MRI-guided planning, for newly diagnosed glioblastoma. It aims to see whether the higher radiation dose can improve treatment while staying safe for nearby critical brain structures.
Aarhus, Central JutlandAges 18 years+ - NCT05768035RecruitingPhase 1/Phase 2
Testing SMART101 after half-matched stem cell transplant
This trial studies a new immune treatment called SMART101 given after a half-matched (haploidentical) stem cell transplant that uses post-transplant cyclophosphamide to prevent complications. It mainly checks safety, and may also look at how well SMART101 helps people with blood cancers recover after transplant.
MarseilleAges 18 years+ - NCT05767619Recruiting
Digital tool to guide care for chest pain calls
This trial tests a digital decision-support tool that helps emergency teams manage people who call for help because of chest pain. It may improve how safely and consistently chest pain is assessed and treated in the ambulance setting.
Kungsbacka, Region HallandAges 18 years+ - NCT05768048Recruiting
Study tracks SMA patients with specific gene changes
This study follows people with spinal muscular atrophy (SMA) who have a particular genetic change in the SMN1 gene. It compares long-term outcomes for those who do and do not receive disease-modifying treatments, to better understand what helps over time.
GenovaAges Any age - NCT05768178RecruitingPhase 2/Phase 3
Vemurafenib plus cobimetinib for BRAF-mutant cancers
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
BelfastAges 18 years+ - NCT05768529RecruitingPhase 1/Phase 2
Study drug U16 for relapsed or refractory CD20 lymphoma
This trial tests U16 in people with CD20-positive non-Hodgkin lymphoma that has come back or not responded after prior treatments. It may help your immune system attack the lymphoma, and researchers will check safety and early signs of benefit.
Changsha, HunanAges 18–70 - NCT05768477Recruiting
Testing different treatments for chronic pain patients
This study looks at different ways to treat long-term (chronic) pain. You may be invited to participate if you’re an adult with chronic pain and can understand the study information.
GhentAges 18 years+ - NCT05768919RecruitingPhase 1/Phase 2
Liposomal curcumin with radiation and temozolomide for new brain cancer
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05769036Recruiting
Biventricular vs left bundle pacing for heart failure outcomes
This trial compares two types of heart pacing to see which improves outcomes for people with heart failure. It may help those who need pacing to better coordinate heartbeats and relieve symptoms.
TomskAges 18–80 - NCT05769660RecruitingPhase 1
Study BEY1107 plus temozolomide for recurrent glioblastoma
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
SeoulAges 19 years+ - NCT05770037RecruitingPhase 2/Phase 3
Alectinib for ALK-positive cancers in teens and adults
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
BelfastAges Any age - NCT05770102RecruitingPhase 2/Phase 3
Atezolizumab for cancers with high mutation or immune markers
This trial tests atezolizumab, a cancer immunotherapy, for people whose tumors have high mutation levels (TMB), or are “MSI-high,” or have CMMRD. It may help shrink cancer or slow its growth by boosting the immune system’s ability to recognize the tumor.
BelfastAges Any age - NCT05770544RecruitingPhase 2/Phase 3
Entrectinib for ROS1 fusion cancers with matching gene test
This trial studies entrectinib, a targeted pill, in people whose cancer has a specific gene change called ROS1 fusion. It may help by shrinking tumors that depend on this ROS1 gene switch, and the study requires starting with a new tissue sample and treatment monitoring.
BelfastAges Any age - NCT05770687Recruiting
Testing diabetes heart medicine soon after a heart attack
This study looks at how starting an SGLT2 inhibitor (a diabetes medicine) around the time of a heart attack affects heart outcomes and heart muscle changes over time. It may help you and your care team understand whether this timing is beneficial after a PCI procedure.
SeoulAges 19 years+ - NCT05770765Recruiting
Biobank for infections and tropical diseases
This study sets up a library (biobank) of biological samples and related health data from people with infectious or tropical diseases. Your samples and information help researchers study these illnesses and develop better tests or treatments.
Negrar, VeronaAges Any age - NCT05771181RecruitingPhase 2
Test vitamin E plus two cancer drugs for metastatic colon cancer
This trial tests whether adding vitamin E to two cancer medicines (fruityquintinib and tislelizumab) can work better in people with metastatic colorectal cancer that is mismatch-repair stable (MSS). It may help if your cancer has grown despite standard treatment, and you can meet the study’s safety and blood/organ requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05772208RecruitingPhase 3
New treatment plan for nasopharyngeal cancer after EBV DNA stays detectable
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05773638Recruiting
Study blood clots and heart disease in adults with Von Willebrand
This study looks at cardiovascular problems and blood-clot events (like deep vein clots or pulmonary embolism) in adults with Von Willebrand disease in western France. It may help doctors better understand who is at risk and how to manage these complications.
AngersAges 18 years+ - NCT05775432Recruiting
Study outcomes for people receiving heart transplants
This study follows people with severe (end-stage) heart failure who are evaluated for and receive a heart transplant. It helps doctors understand what outcomes to expect after transplant, which can guide future care.
Xi'an, ShaanxiAges 3–80 - NCT05775523Recruiting
Safety follow-up study for children using lonapegsomatropin
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
Phoenix, ArizonaAges 1–18 - NCT05776069RecruitingPhase 1/Phase 2
Test drug VGA039 for bleeding control in von Willebrand disease
This Phase 1/2 study tests VGA039 in healthy adults and people with von Willebrand disease (VWD). The goal is to see if the drug is safe and how it affects bleeding-related factors, especially in people who have symptoms.
Los Angeles, CaliforniaAges 12–60
Hear when a new Patient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient?
- Yes. Clin2 currently lists 14,857 recruiting patient studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.